Abstracts tagged "drug therapy and methotrexate (MTX)"

Abstract Number: 489 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Toxicity of Methotrexate Monotherapy in Daily Clinical Practice. Results from an Early Arthritis Clinic
Christian A. Waimann^1,2, Margarita Landi³, Fernando Dal Pra³, Gustavo Citera⁴, Maria Celeste Orozco⁴, Osvaldo Luis Cerda³, Federico Ceccatto⁵, Sergio Paira⁵, Francisco Colombres⁶, Alberto Berman⁷, Horacio Berman⁷, Anastasia Secco⁸, Marta Mamani⁸, Maritza Manzano⁸, Maria Victoria Martire⁸, Francisco Caeiro⁹, Maria Haye Salinas¹⁰, Alejandro J. Alvarellos¹⁰, Ana C. Alvarez¹⁰, Javier Rosa¹¹, Valeria Scaglioni¹², Enrique R. Soriano¹¹, Josefina Marcos¹³, Mercedes Argentina García¹⁴, AC Costi¹⁵, Alejandro Martinez¹⁶, Oscar Luis Rillo¹⁶, Edson Veloso¹⁷, Ricardo V. Juárez¹⁸, Maria Elena Crespo¹⁹, Ana Quinteros²⁰, Doralia Vasquez²⁰, C Ledesma²¹, Gabriela Salvatierra²¹, R Quintana²², Monica Sacnun²³ and Marcelo Abdala²⁴, ¹Rheumatology, Hospital Dr. Hector Cura, Olavarria, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁶Tucuman, Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁸Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁰Rheumatology, Hospital Privado de Córdoba, Córdoba, Argentina, ¹¹Hospital Italiano, Buenos Aires, Argentina, ¹²Rheumatology, Hospital Italiano, Buenos Aires, Argentina, ¹³HIGA San Martín, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín, La Plata, Argentina, ¹⁵Rheumatology, HIGA San Martín, La Plata, Argentina, ¹⁶Rheumatology, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, ¹⁷Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ¹⁸Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁹Hospital Señor del Milagro, Salta, Argentina, ²⁰Centro Integral De Reumatologia, Tucumán, Argentina, ²¹Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²²Rheumatology, Hosp. Provincial, Rosario, Argentina, ²³Hosp. Provincial, Rosario, Argentina, ²⁴Hospital Provincial del Centenario, Santa Fe, Argentina
Background/Purpose: Several trials had reported the efficacy and toxicity of methotrexate monotherapy in patients with early rheumatoid arthritis. However, patients outside clinical trials could be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].